SIRS-ESWT Trial: Shoulder Internal Rotator Spasticity Trial Treated With Extracorporeal Shock Wave Therapy Trial
Effects of Extracorporeal Shock Wave Therapy on Shoulder Internal Rotator Spasticity in Post-Stroke Patients: A Randomized Controlled Trial
National Taiwan University Hospital
40 participants
Jul 23, 2025
INTERVENTIONAL
Conditions
Summary
Extracorporeal shock wave therapy (ESWT) has shown potential in reducing post-stroke limb spasticity. This study aims to evaluate the efficacy of focused ESWT on shoulder internal rotator spasticity in post-stroke patients.
Eligibility
Inclusion Criteria5
- Patients aged 18 years or older with unilateral cerebral stroke.
- Restricted passive external rotation of the spastic shoulder by more than 20 degrees.
- A Modified Ashworth Scale score of 1 or higher for shoulder internal rotator spasticity.
- Stable medical condition and vital signs.
- Clear consciousness, able to follow instructions.
Exclusion Criteria5
- History of two or more strokes, traumatic brain injury, brain tumors, or other cerebral disorders.
- Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal conditions affecting muscle tone assessment.
- Ineligibility for shock wave intervention due to malignancies, coagulation disorders, localized infections, or presence of a pacemaker.
- Prior shock wave intervention or botulinum toxin injection for post-stroke spasticity within the past three months.
- Inability to participate in interventions or functional assessments due to cognitive, consciousness, or language impairments.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
Placebo shockwave therapy directed at subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06674785